The ubiquitin proteasome system (UPS) has been recognized as a key regulatory pathway in cardiovascular diseases. Although the role of this system in the pathogenesis of endothelial dysfunction remains largely unknown, available data suggest that proteasome activity is modified by mediators and processes-e.g. nitric oxide and oxidative stress-involved in the regulation of endothelial function. In addition, there is some evidence that the UPS itself modulates the activity of endothelial nitric oxide synthase, the key enzyme of vascular homeostasis, interacts with other vasoactive mediators involved in regulation of endothelial function, influences oxidative stress response in the vasculature, and thereby contributes to regulation of endothelial (dys)function. This review discusses the potential implications of the UPS in endothelial dysfunction.
Introduction
Alterations in the ubiquitin proteasome system (UPS) † have been shown to contribute to the pathogenesis of several diseases, including cancer, neurodegenerative, and immune diseases. 1, 2 The central importance of the UPS in quality control of proteins, control of the cell cycle, transcription factor regulation, gene expression, cell differentiation, and immune response-together with its emerging role in the pathogenesis of atherosclerosis-raises the question of whether the UPS could be involved directly or indirectly in the initial phase of vascular damage, i.e. in the process of endothelial dysfunction. 3 -7 Endothelial dysfunction is considered to be an early and crucial event in the pathogenesis of atherosclerosis and to be closely associated with risk factors for atherosclerosis, coronary artery disease, and cardiovascular events. 8, 9 In this review, we outline current data on interaction of the UPS with endothelial dysfunction. We thereby address the following two issues: whether the UPS and/or its function is modulated by events involved in endothelial dysfunction and whether the UPS itself affects processes leading to endothelial dysfunction.
The ubiquitin proteasome system
The UPS is the major non-lysosomal intracellular proteolytic system responsible for degradation of presumably thousands of proteins, particularly those of short-lived and regulatory nature. Degradation of proteins by the UPS occurs in two steps, including targeting of proteins and successive degradation by the 26S proteasome. 2, 10 Attachment of ubiquitin or ubiquitin-like proteins (UBL) is the dominant mechanism to tag proteins for degradation by the 26S proteasome. Initially, the ubiquitin-activating enzyme, E1, activates the 76 amino acid protein ubiquitin in an ATP-dependent manner and transfers it to one of several ubiquitin-conjugating enzymes (UBCs), E2s. These UBCs carry the activated ubiquitin to E3s, ubiquitin-protein ligases that specifically bind to the substrate and catalyze the covalent attachment of ubiquitin to a specific Lys residue of the target protein. This monoubiquitination enables further recognition by ubiquitin-binding domains (UBDs) within the target protein. In further steps, polyubiquitin chains are synthesized by additional transfer of activated ubiquitin to internal Lys residues. Depending on the binding site, Lys-48 or Lys-63, the polyubiquitin chains are different in structure, which allows differential recognition by UBDs and deubiquitinating enzymes (DUBs, see below). Moreover, Lys-48-linked chains serve primarily as recognition markers for proteasomal binding and degradation, whereas Lys-63-linked chains are apparently also involved in the regulation of protein trafficking, DNA repair, and signal transduction. 2, 10, 11 UBLs, evolutionary ubiquitin precursor systems, use in part related elements of the ubiquitination pathway to mark target proteins. 12 To date, more than 10 UBLs have been identified including interferon-stimulated gene product (ISG15) and small ubiquitin-related modifier (SUMO). A general function of UBL attachment is to facilitate interaction of the substrate with other proteins by mechanisms such as providing additional binding sites or causing conformational changes that enhance binding. 12 The ubiquitin system has a strict hierarchical architecture. 13 Only one known enzyme, E1, activates ubiquitin for all further modifications. With respect to downstream elements of the ubiquitination cascade, the human genome encodes not only for more than 20 UBCs (E2s), but also for more than 1000 ubiquitin-protein ligases (E3s). According to structural similarity, the latter can be attributed to several families including HECT domain and RINGfinger domain-containing E3s representing the major and U-box and PHD domain-containing E3s representing the smaller families.
The number and variety of E3s endow substrate specificity. 13 The 26S proteasome complex is a multicatalytic protease consisting of a 20S catalytic core and two 19S regulatory particles (RPs). Ubiquitin receptors and subunits in the RP allow binding of the substrate. The 19S RP consists of a ring of ATPases that are required to unfold the substrate and to open the entry pore of the 20S complex. The 20S complex is a barrel-like structure with two-fold symmetry that is composed of four stacked rings (two a and two b rings) of seven subunits. 2, 11 The proteolytically active sites are located in both b rings and conferred by the b-subunits b 1 , b 2 , b 5 . These constitutional subunits can be replaced by IFN-g inducible subunits LMP2, MECL1, and LMP7 generally referred as to immunosubunits. Immunoproteasomes reportedly have an altered cleavage site preference as well as a different cleavage rate of target proteins. 13 Once the unfolded protein is inserted into the 20S complex, it is degraded into fragments of 3-25 amino acids length, and ubiquitin is released and recycled by DUBs.
14 Around 100 DUBs have been identified with several functions: they regenerate and recycle ubiquitin, reverse ubiquitination of target proteins, and cotranslationally activate ubiquitin proproteins. The diversity of these functions is manifold, a role of DUBs has been described in cellular Reliable, sensitive assays are essential for monitoring proteasome activity. Among them, peptide-conjugated fluorophores are widely used as substrates for monitoring all three proteasome activities including chymotrypsin-like (cleavage after hydrophobic residues), trypsin-like (cleavage after basic residues), and caspaselike (cleavage after acid residues) activity. 13 The most common method used to measure ubiquitin and ubiquitinated proteins are various methods of anti-ubiquitin immunoblotting including epitope-tagging and radiolabelling. 17 For general screening of the UPS, several microarrays have been developed containing more than 1000 genes and allowing the detection of mRNA expression changes along the entire UPS pathway.
Interaction of the UPS with mediators and pathways involved in regulation of endothelial function/dysfunction
A cardinal feature of endothelial dysfunction is impaired endothelium-dependent vasodilation caused by loss of nitric oxide (NO) bioavailability. 18 No one single mechanism can explain endothelial dysfunction: rather, a complex interplay of multiple regulatory pathways leading to decreased NO production and/or increased NO inactivation is involved in the pathogenesis of this vascular disorder. In addition, an imbalance between endothelial-derived relaxing and contracting factors as well as defects in their downstream signalling cascades may contribute to the development of endothelial dysfunction.
UPS and NO
NO is synthesized from L-arginine by isoforms of nitric oxide synthases (NOS), after which it freely diffuses into adjacent vascular smooth muscle cells (VSMCs). There, it activates soluble guanylate cyclase (sGC), thereby leading to conversion of GTP to cGMP, and to vasodilation. 19 Recent data suggest that NO stimulates proteasomal function and protects endothelial cells from oxidative stress. 20, 21 An increase in NO generation in response to low concentrations of hydrogen peroxide (H 2 O 2 ) induced proteasome activation, whereas a decrease in NO was associated with a reduction in proteasome activity. 20 -22 Both endogenous and exogenous NO enhanced chymotrypsin-and trypsin-like activities of the 26S proteasome in bovine aortic endothelial cells (BAEC) treated with H 2 O 2 . 20 In turn, pretreatment with proteasome inhibitors abrogated NO-mediated effects. The increase in proteasome activities was shown to be secondary to an NO/cGMP/cAMP-induced immunoproteasome subunit expression (LMP2 and LMP7) in endothelial cells. 23 NO enhanced phosphorylation of the transcription factor cAMP-response element-binding protein, thereby elevating cAMP-response element-promoter activity and inducing the expression of LMP2 and LMP7. Greater expression of these subunits was associated with enhanced proteasome activity. NO-dependent increase in proteasome activity was attenuated by protein kinase A and G inhibitors and was completely prevented in cells transfected with antisense LMP2 and LMP7 oligonucleotides. 23 Lower levels of LMP2 and LMP7 were detected in the aorta of iNOS knockout mice, which emphasize that endogenous production of NO is indeed important in regulation of the immunoproteasome. These results suggest that an NO-mediated immunoproteasome signalling pathway increases proteasome activity and affords cytoprotection in endothelial cells. 23 
UPS and NOS regulation
Since NO is a highly diffusible gas that cannot be stored in intracellular compartments, modulation of the activity of the three distinct NOS primarily regulates NO signalling. 24 -26 The endothelium has a constitutive supply of NO from endothelial NOS (eNOS) that is Ca 2þ -dependent and that generates low levels of NO. 27 In contrast, the inducible isoform of NOS (iNOS), which is expressed in response to inflammatory stimuli, acts in a Ca 2þ -independent manner and produces larger amounts of NO. 26, 27 The third isoform (neuronal NOS) is mainly implicated in neuronal diseases and plays a minor role in the vasculature. The UPS is the major proteolytic system responsible for regulated degradation of all NOS enzymes.
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3.2.1 UPS and eNOS regulation eNOS is controlled by multiple means, including transcriptional regulation, post-translational modification, interactions with proteins such as Hsp90 and caveolin, availability of cofactors such as tetrahydrobiopterin (BH4), activation through Ca 2þ , as well as phosphorylation/dephosphorylation. 31 -33 Few data are available with regard to involvement of the UPS in regulation of eNOS expression and activity. Jiang et al. have shown that the Hsp90 inhibitor geldanamycin induces eNOS ubiquitination and its subsequent protein degradation. 34 The E3 ligase CHIP (COOH terminus of heat shock protein 70-interacting protein) has been shown to modulate the chaperone substrate eNOS in a manner independent of its ubiquitin ligase activity.
CHIP inactivates eNOS by uncoupling its interaction with Hsp90 and by displacing eNOS from the Golgi transit pool. 34 In addition, proteolytic degradation of eNOS may play a role in post-ischaemic endothelial dysfunction. Loss of eNOS activity after ischaemia has been shown to result from a combination of intracellular acidosis-dependent protein denaturation leading to proteolytic degradation. 35 The effects of proteasome inhibitors on eNOS expression in endothelial cells and in vivo have been assessed in several studies. We have shown that proteasome inhibition (PI) modulates eNOS expression in a dose-dependent biphasic manner. Whereas higher doses of proteasome inhibitors led to downregulation of eNOS, low concentrations up-regulated expression and activity in various vascular endothelial cells. 36, 37 Upregulation of eNOS after PI occurred via de novo protein synthesis and was not secondary to accumulation of eNOS in response to reduced degradation after PI. 36 Since we observed PI-induced nuclear translocation of the transcription factors Sp1 and JunD and since the eNOS promoter contains consensus binding sites for Sp1 and AP1, 38 our results suggest that both transcription factors may be involved in upregulation of eNOS after PI. Cokic et al. 39 also
reported increase in eNOS expression and NO generation in HUVEC under low-dose treatment with MG132 (0.02-0.5 mM).
Similarly, a significant increase in eNOS expression and NO generation has been shown in BAEC in response to a higher dose of lactacystin (10 mM). 22 Two other reports found no significant changes in eNOS expression. In both studies, the proteasome inhibitors were applied in markedly higher, essentially cytotoxic doses. 40, 41 In TNFa-induced endothelial dysfunction in rat aortic rings, we found slight upregulation of eNOS after incubation of the rings with TNFa, and marked downregulation of eNOS after concomitant inhibition of the proteasome (MG132 100 nM). 42 The favourable effects of PI on endothelial function were secondary to antioxidative mechanisms. Under conditions of reduced ROS generation and with decreased scavenging of NO by superoxide, we assumed that the expression of eNOS would be lessened in terms of negative feedback regulation, i.e. in order to avoid an excess of NO harmful to the vascular system. 42 In vivo, 3 months treatment of hypercholesterolaemic female pigs with the proteasome inhibitor MLN-273 led to increased eNOS expression in the coronary arterial wall. However, this increase was not associated with amelioration of endothelial function: rather, with worsening (see below). eNOS uncoupling was incriminated as underlying reason. 5 Thus, the effects of PI on eNOS expression evidently vary strongly depending on the experimental model, the dose of the proteasome inhibitor, and the duration of treatment. Data on UPS and eNOS phosphorylation are sparse. In vitro, treatment of endothelial cells with high doses of different proteasome inhibitors (MG132, 10 mM, lactacystein, 20 mM) led to eNOS serine 1179 dephosphorylation and consequent decrease of enzymatic activity. The phosphorylation status of eNOS threonine 497 and serine 635 remained unchanged. 41 Proteasome inhibitorinduced effects on eNOS dephosphorylation were due to ubiquitination of protein phosphatase 2A (PP2A), a ubiquitous serine/ threonine phosphatase that dephosphorylates proteins with poor substrate specificity. 43 Ubiquitinated PP2A translocates from the cytosol to the cell membrane, associates with eNOS, and thereby dephosphorylates eNOS and its upstream kinase Akt. 43 Post-translational modification of eNOS via interaction with a variety of regulatory and structural proteins represents a further mechanism in the control of NO-dependent effects in vasculature. eNOS activity is regulated by its localization in caveolae by interaction with several proteins. 44 Hsp90 binding enhances eNOS activity by increasing calmodulin affinity to eNOS and by reducing binding of the inhibitory protein caveolin-1. 44 -47 In addition, Hsp90 recruits serine/threonine kinase Akt to the Hsp90/eNOS complex, which facilitates eNOS phosphorylation by Akt, an event associated with increased NO production. 45 -47 Few data are available with regard to the role of UPS in regulation of these interactions in endothelial cells. Inhibition of Hsp90 by geldanamycin has been shown to induce proteasomal degradation of sGC subunits. 48 The chaperone-dependent E3 ligase CHIP, which downregulates exogenous and endogenous sGC, ubiquitinates sGC a1-and sGC b1-subunits in intact cells and in vitro and prepares the sGC heterodimer for proteasomal degradation. 34, 49 Some evidence exists that various cardiovascular diseases are associated with downregulation of the activity and expression of the NO receptor sGC. 50 eNOS uncoupling is one major cause of reduced NO availability in endothelial dysfunction, particularly in diabetes. 51 The most important underlying mechanism is BH4 deficiency. 31 In this case, eNOS becomes 'uncoupled', whereby electrons no longer flow to L-arginine to form NO but, instead, reduce molecular oxygen to generate superoxide (O 2 2 ). 52, 53 Thus, under these conditions, eNOS itself can produce reactive oxygen species (ROS) rather than NO. Recent data suggest that the 26S proteasome degrades guanosine 5 0 -triphosphate (GTP)-cyclohydrolase I (GTPCH), which is the rate-limiting enzyme for de novo biosynthesis of BH4. 54 Thus, chronic hyperglycaemia is associated with endothelial dysfunction, primarily by induction of oxidative stress and by reduction in levels of BH4 via 26S proteasomal degradation of GTPCH. 54 Inversely, treatment of mice with streptozotozin-induced diabetes by MG132 reversed the reduction of GTPCH and BH4, and abolished diabetes-induced endothelial dysfunction. 54 Since hyperglycaemia increases superoxide anion production and since overexpression of superoxide dismutase (SOD) reduces hyperglycaemia-induced 26S proteasome activation and GTPCH reduction, proteasome activation is apparently dependent on endogenous free radical generation. Acceleration of GTPCH degradation by the UPS may have important implications for development of vascular endothelial dysfunction in diabetics. Since inhibition of GTPCH reduction by PI may increase levels of BH4, PI may offer useful tools for maintenance of BH4 levels, which consequently prevent eNOS uncoupling in cardiovascular diseases. Dihydrofolate reductase (DHFR), another enzyme implicated in eNOS uncoupling, is also substrate for the proteasome. DHFR, which catalyzes the regeneration of BH4 from its oxidized form, dihydropterin, is critical for BH4 and NO bioavailability. 55 There is some evidence that angiotensin II (Ang II) downregulates DHFR in an H 2 O 2 -dependent manner and that this response is involved in Ang II-induced BH4 deficiency and eNOS uncoupling. These signalling events have been incriminated in eNOS dysfunction under situations associated with oxidant stress. 55 DHFR is proteolyzed by the 20S proteasome and this degradation is increased under oxidative conditions. 56, 57 For other players involved in eNOS regulation, NO generation and endothelial dysfunction-such as L-arginine, arginase, asymmetric dimethylarginine, and dimethylarginine dimethylaminohydrolase-there has until now been no sufficient evidence that they are substrates of degradation by the proteasome, nor that they are indirectly modulated by the UPS.
UPS and iNOS
In contrast to eNOS, which is regarded as constitutive, iNOS is expressed in most vascular cells only after induction by stimuli such as lipopolysaccharide, proinflammatory cytokines, and shear stress. 58 Accordingly, iNOS expression has been implicated in endothelial dysfunction primarily in the context of inflammatory diseases. 59, 60 Activation of iNOS is associated with production of great amounts of NO. Not only reduced NO availability, but also excessive production of NO is in fact harmful for endothelial cells and is believed to be associated with endothelial dysfunction. 61 Indeed, large quantities of NO may interact with superoxide anions to form peroxynitrite (ONOO 2 ). Peroxynitrite is not only cytotoxic, but also oxidizes BH4-thereby reducing availability of BH4 for eNOS and promoting eNOS uncoupling. 62 -64 Treatments that prevent iNOS activation restore endothelial fucntion. 65 iNOS activity can be controlled through regulation of its synthesis, catalytic activity, and degradation, the latter occurring by the UPS with dependence on CHIP. 66, 67 Proteasome inhibitor treatment induces accumulation of iNOS by blocking degradation of the nuclear factor-kB (NF-kB) inhibitor IkB-a, thus preventing activation of NF-kB, which is an important transcription factor involved in iNOS induction.
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Interaction of UPS with other vasoactive mediators
Endothelial function is further influenced by the balance between various vasoactive factors, including endothelium-dependent relaxing factors (EDRF) and endothelium-dependent contracting factors (EDCF). 68 Endothelial dysfunction is accompanied by deterioration in this balance, with progressive reduction in vasodilating factors [NO, prostanoid vasodilators, endothelium-dependent hyperpolarizing factor (EDHF)], and with an increase in production of vasoconstricting mediators [endothelin-1 (ET-1), Ang II, and cyclooxygenase (COX)-derived vasoconstricting factors]. 68 -73 ET-1, one of the most important vasoconstrictors, is considered to be the natural counterpart of NO and to play a major causative role in the development of endothelial dysfunction. 73 There are several lines of evidence that the UPS is involved in regulation of the endothelin system. Proteasome inhibitor treatment led to a decrease of ET-1 content in the aortic wall of DOCA salt-sensitive rats. 76 In addition, suppression of basal and TNFa-induced ET-1 release in porcine aortic cells was observed under pretreatment with bortezomib, possibly through reduction of NF-kB activation. 77 We have recently shown that treatment of HUVEC with non-toxic doses of proteasome inhibitors (MG132 70 nM, MG262 4 nM) markedly reduced ET-1 expression and, moreover, significantly downregulated ET-A expression. 37 In addition, treatment of rat aortic rings with TNFa upregulated prepro-ET-1 mRNA, whereas co-treatment with proteasome inhibitors completely blunted this increase. 42 Ang II has been implicated in endothelial dysfunction, chiefly by induction of oxidative stress. 71 and AT 2 receptors undergo ubiquitination-dependent proteolysis. 78, 80 Second, Ang II activates the 26S proteasome via peroxinitrite-induced tyrosine nitration of 19S RP (PA700). The subsequent enhanced association of PA700 with the catalytic 20S complex accelerates GTPCH I degradation, which results in BH4 deficiency and consequent endothelial dysfunction. 79 Hence, activation of the UPS appears to be causally involved in Ang II-mediated endothelial dysfunction. EDRF and EDCF, which contribute to moment-to-moment changes in vascular tone, mainly depend on the activity of endothelial COX. Depending on the vascular bed and (patho)physiological conditions, some of the COX-derived factors exhibit vasorelaxant or vasoconstrictor activity. 81 Two isoforms exist:
COX-1 and COX-2. 82 COX-1 is constitutively expressed in most cell types, whereas COX-2 is an inducible isoform that mediates pathological effects in inflammatory disorders. The COX-1-derived prostanoids prostaglandin H 2 and thromboxane A 2 (TXA 2 ) are generated by the endothelium and circulating blood cells and contribute to endothelium-dependent contractions via activation of thromboxane-prostanoid (TP) receptors on VSMC. 83, 84 Under conditions in which COX-2 is induced, this isoform also contributes to endothelial dysfunction by producing vasoconstrictor prostanoids. 85 Whereas the mechanism of COX-1 degradation is still unclear, it has been demonstrated that COX-2 is substrate of the 26S proteasome. 81, 82, 86 Its degradation involves processing of the N-linked oligosaccharide at Asn594, unfolding presumably by ER chaperones such as BiP and calnexin, retrograde transport to the cytoplasm via the ER-associated degradation, and finally ubiquitination and proteolysis by the proteasome. 81, 82 There is some evidence that UPS-dependent degradation of COX-2 is regulated by the COP9 signalosome and is differentially influenced by COX inhibitors.
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PGI 2 , the predominant prostaglandin produced by endothelial cells, is generated by both COX isoforms. PGI 2 promotes vasodilation in most vascular beds through activation of IP receptors-which leads to stimulation of adenylyl cyclase and subsequent increased production of cAMP. 88 PI (lactacystin) has been shown to increase COX activity, arachidonic acid release, and PGI 2 production. 89 Endothelial-derived hyperpolarizing factor (EDHF) contributes to endothelial-dependent vasodilation when the bioavailability of NO is substantially reduced. Binding of acetylcholine, bradykinin, or substance P to their endothelial receptors, as well as increase in shear stress, stimulates the synthesis of EDHF. 69 The identity of EDHF is unknown. The mechanisms of EDHF-type relaxations involve release by the endothelium of hydrogen peroxide, epoxyeicosatrienoic acids, potassium ions, and electronic communication through the gap junctions. EDHF can passively diffuse from the endothelium to activate calcium-activated potassium (K Ca ) channels located in the SMC, thereby promoting membrane hyperpolarization and the release of K þ . 69 In addition, EDHF can facilitate activation of endothelial K Ca channels directly mediated by Ca 2þ , which induces hyperpolarization of endothelial cells and the release of K þ . 69 Although there is no direct evidence that UPS modulates EDHF-mediated effects, an interaction is likely since as shown in HEK293 cells, K Ca channels are degraded by the UPS. 90 In addition, endothelial receptors of vasoactive agonists stimulating EDHF release are substrate for proteasomal degradation (see below).
Multiple vasoactive agonists such as ET-1, Ang II, TXA 2 , PGI 2 , bradykinin, and acetylcholine act by binding to specific GPCRs on the surface of endothelial cells. 71, 74, 83, 91 There is some evidence that a defect in GPCRs or their downstream cascades contribute to explain impaired endothelial-dependent vasorelaxation.
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The UPS has been shown to play a role in GPCR turnover and in regulation of GPCR-initiated signalling pathways. 94, 95 Thus, a number of GPCRs (i.e. Ang II receptors, muscarinic acetylcholine receptors, or b 2 -adrenergic receptors) and proteins that directly associate with them (i.e. b-arrestin and GPCR kinase) are ubiquitinated. 80, 91, 94, 96 On the other hand, PI prevents G protein degradation, upregulates adenylate cyclase activity and intracellular cAMP content, and reduces inositol 1,4,5-triphosphate receptor ubiquitination and degradation.
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UPS and oxidative stress
The pathogenic role of oxidative stress in the process of endothelial dysfunction is well established. 99 The susceptibility of endothelial cells to oxidative stress is a function of the overall balance between generation of endogenous and exogenous ROS, the activity of pro-oxidative enzymes (NADPH oxidase, xanthine oxidase, uncoupled eNOS, lipoxygenase, COX, glucose oxidase, and the mitochondrial respiratory chain) and antioxidant enzymes [SOD, glutathione peroxidase (GPX), haem oxygenase, thioredoxin peroxidase/peroxiredoxin, catalase, and paraoxonase]. 99, 100 The sources of ROS are a variety of cell types, including 
. 99 ROS are generated as by-products of oxygen metabolism and are essential for regulation of basic cell functions. 22 Whereas nontoxic oxidative stress may stimulate growth and proliferation, excessive ROS production is toxic by oxidative modification of proteins and lipid membranes, which is reflected by increased levels of protein carbonyls and of aldehydes as end products in lipid peroxidation. 101 In addition, ROS reduce bioactive NO through chemical inactivation or may lead to formation of the highly reactive intermediate peroxynitrite, which can in turn uncouple eNOS. 102 Enhanced NO inactivation caused by excess ROS generation, rather than decreased NO production, evidently plays an important role in the impairment of endotheliumdependent vasodilation. The amount of oxidatively modified proteins and lipid products in the vessel wall depends on their production rate as well as on the rate of repair or removal of these products by the UPS; 90% of oxidized proteins are degraded by the 26S proteasome. 103 Mild protein oxidation promotes an increase in proteasomal degradation, whereas higher oxidative stress is associated with protein crosslinking and formation of indegradable aggregates that inhibit the proteasome and further increase oxidative damage. 104 Dealing with the interaction of UPS and oxidative stress raises two further questions: how oxidative stress modulates proteasomal function and, in turn, how UPS affects the generation of ROS.
UPS as a target of oxidative stress
There are several lines of evidence to support the conclusion that non-toxic oxidative stress is able to stimulate proteasomal function. Chymotrypsin-like activity increased in BAEC stimulated with 4-hydroxy-2-nonenal (4-HNE). 105 Similarly, ONOO 2 augmented chymotrypsin-like activity in HUVEC exposed to hyperglycaemia. 54 Changes in proteolytic activity in the transition from non-toxic to toxic oxidative stress are mirrored in a biphasic response. An increase in chymotrypsin-like activity after mild ox-LDL challenge of human endothelial cells was observed within 5 h, whereas toxic doses induced a biphasic response with early and rapid increase in activity after 2 h, followed by profound decay after 5 h. 106 Correspondingly, a bell curve for chymotrypsinlike and trypsin-like activities has been found as a function of increasing doses of H 2 O 2 . 22 Under toxically high ROS concentrations, modifications of proteasomal subunits have been identified as target structures of oxidative modification. 23,107 -109 These modifications were accompanied by the reduction of proteasome activities followed by altered recognition and processing of substrates. Scant data has until now become available on the interplay between vascular stress and the function of UPS in human vascular disease. In a study with endarterectomy specimens, oxidative stress mirrored by p67phox expression, a subunit of NADPH oxidase, was inversely correlated with proteasome activity in unstable plaques-an observation suggestive that increased oxidative stress in human carotid plaques suppresses proteasome activity. 110 Thus, the available data suggest a biphasic interaction between oxidative stress and the proteasome. Whereas non-toxic oxidative stress enhances proteolytic activities, toxic stress is associated with suppression of proteasomal function. This can be explained by the fact that, in this context, the proteasome itself becomes the subject of oxidative modification.
Effects of UPS on oxidative stress
We have performed in vitro analysis of the effects of short-term PI on intracellular ROS generation, ROS-generating enzymes, as well as on members of the endothelial defence system in HUVEC, by gene expression profiling and by determination of dichlorofluorescein as a parameter of ROS formation. 37 To dissect the effects of various degrees of PI, a low, non-toxic dose (70 nM MG132) not affecting cell viability and not activating proapoptotic pathwaysand a high, toxic dose (200 nmol/L MG132) that hampers viability and leads to apoptosis were investigated. 37 In these experiments, In vivo data regarding PI and oxidative stress are sparse. Treatment of pigs on high-cholesterol (HC) diet with the proteasome inhibitor MLN-273 led to a 70% decrease in chymotrypsin-like activity in coronary arteries (see above). 5 An increase in oxidative stress parameters was found: PI enhanced DHE fluorescence in the coronary intima. Moreover, nitrotyrosine, 4-HNE-modified proteins, and expression of NADPH subunit p47phox were higher under PI. Accordingly, hypercholesterolaemia-induced oxidative stress in the endothelium was further aggravated by PI. 5 We investigated the effects of bortezomib in Dahl-sensitive rats under highsalt diet (HSD). HSD increased superoxide in the rat aortae; however, in contrast to the previous study, HSD rats had significantly lower superoxide levels under PI. Moreover, serum concentrations of thiobarbituric acid-reactive substances, as parameter of lipid peroxidation, were markedly lower than in controls. 111 
UPS and endothelial (dys)function in vitro, ex vivo, and in vivo
The effects of proteasome inhibitors on endothelial function were tested in various in vitro, ex-vivo, and in vivo models ( Table 1) . We demonstrated that low-dose PI ameliorated endothelial-dependent vasodilation in rat aortic rings in vitro. MG132 pretreatment was associated with significant increase in endothelial-dependent vasodilation in response to acetylcholine in precontracted rat aortic rings. 36 with MG132 dose-dependently abrogated impaired vasorelaxation. As mentioned before, reduced ROS generation and abrogated TNFa-stimulated ET-1 expression after PI contributed to improvement of endothelial function in this model. 42 In addition to these in vitro data, there is some ex vivo evidence that PI has a beneficial impact on endothelial function ( Table 1) . Treatment of mice with MG132 abolished diabetes mellitusinduced reduction in endothelial-dependent vasorelaxation. 54 Prevention of proteasome-dependent GTPCH reduction caused by diabetes was discussed as underlying mechanism. Another study described in vivo a normalization of blunted renovascular and functional responses to acetylcholine in hypercholesterolaemic pigs treated with proteasome inhibitors. 116 Renal endothelial function improvement was accompanied by decreased renal ET-1 and NF-kB and by enhanced eNOS expression. 116 These data suggest beneficial effects on endothelial function/dysfunction after treatment with proteasome inhibitors in low doses. However, results are not uniform. In studies of female pigs under HC diet, hampered endothelial-dependent vasodilation was found in those animals that were treated for 3 months with MLN-273 ( Table 1) . 5 Under chronic proteasome inhibitor treatment, there was significantly greater expression of eNOS as well as higher concentrations of oxidative stress parameters, including dihydroethidium, nitrotyrosine, and NADH(P)H oxidase subunit p47phox. eNOS uncoupling was incriminated as potential underlying mechanism in explanation of increased eNOS expression, together with impaired endothelial function. 5, 116 Taken together, the effects of PI on endothelial function evidently depend on multiple variables, e.g. dosage and duration of proteasome inhibitor treatment, species, as well as the vessel or cell type studied. In support of this hypothesis, endothelial function in hypercholesterolaemic pigs treated with proteasome inhibitor was improved in renal and impaired in coronary circulation. 6, 90 
Conclusions
Although the exact relationships are only beginning to be understood, a puzzle consisting of many pieces of evidence suggests that the UPS must be considered a modulator of endothelial (dys)-function by interaction with several essential regulatory pathways.
There is some evidence that NO as well as non-toxic oxidative stress increase proteasome activity, whereas severe oxidative stress is associated with suppression of proteasomal functionpresumably as a consequence of oxidative modification of the proteasome itself. In turn, in vitro and in vivo studies have shown that the UPS itself modulates eNOS expression and phosphorylation, influences the availability of cofactors and proteins involved in eNOS activation, regulates endothelial-dependent contracting and vasodilating factors, and interacts with oxidative stress response in endothelial cells. Most studies have used inhibitors of the proteasome to obtain insights on its impact into the development of endothelial (dys)function. In accordance with the experimental system-and, most notably, with the dose and duration of treatment of the proteasome inhibitor-the results of studies are partially conflicting and are not readily capable of being subsumed into a conclusive pathophysiological concept.
In summary, available data suggest that short-term, non-toxic PI may be beneficial, whereas higher proteasome-inhibitor doses and application over longer periods of time are evidently associated with more disadvantageous effects in the vasculature. A pivotal role may be assigned to the interaction of the UPS and oxidative stress response in vascular cells. Low-dose, short-term PI induces stress response in endothelial cells that is chiefly characterized by the upregulation of key enzymes of the antioxidant defence system, thereby protecting cells from oxidative stress and leading to improved endothelial function. In pathological states with increased ROS generation, long-term PI may further hamper the compensatory response of enhanced processing and degradation of oxidatively modified proteins, thereby aggravating oxidative stress and, in turn, endothelial dysfunction.
